Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iTARGET-Elderly Study
NCT07359105Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ezetimibe in cardiovascular disease (CVD) and dyslipidemia (2 arms). Primary endpoint: Time to first occurrence of a major adverse cardiovascular event at 36 months. Started Mar 2026; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
cardiovascular disease (CVD)dyslipidemia
Beyond the preview
Go deeper on NCT07359105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359105.